These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

613 related items for PubMed ID: 11322250

  • 1. Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients.
    Yerly S, Denereaz N, Mermillod B, Hirschel B, Perrin L.
    Antivir Ther; 1996 Aug; 1(3):167-71. PubMed ID: 11322250
    [Abstract] [Full Text] [Related]

  • 2. Reverse transcriptase genotype and antiretroviral susceptibility of human immunodeficiency virus isolates from patients with advanced disease treated with didanosine: correlation with virologic response and survival.
    Shepp DH, Ashraf A, Tang IT, Match ME, Millan C, Pergolizzi R.
    J Med Virol; 1996 Aug; 49(4):303-10. PubMed ID: 8877763
    [Abstract] [Full Text] [Related]

  • 3. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
    Flandre P, Descamps D, Joly V, Meiffrédy V, Tamalet C, Izopet J, Aboulker JP, Brun-Vézinet F.
    Antivir Ther; 2003 Feb; 8(1):65-72. PubMed ID: 12713066
    [Abstract] [Full Text] [Related]

  • 4. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
    Rusconi S, De Pasquale MP, Mainini F, Bulgheroni E, Kurtagic S, Gori A, Violin M, Zanchetta N, Moroni M, Balotta C, Galli M.
    Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
    [Abstract] [Full Text] [Related]

  • 5. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Dec; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 6. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
    Bongiovanni M, Gianotti N, Chiesa E, Nasta P, Cicconi P, Capetti A, di Biagio A, Matti A, Tirelli V, Marconi P, de Luca A, Mussini C, Gatti F, Zaccarelli M, Abeli C, Torti C, Antinori A, Castagna A, d'Arminio Monforte A.
    Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
    [Abstract] [Full Text] [Related]

  • 7. [Zidovudine plus didanosine in HIV infected asymptomatic patients previously treated with zidovudine].
    López-Martínez C, Guarner J, Magis-Rodríguez C, Uribe-Zúñiga P, del Río-Chiriboga C.
    Rev Invest Clin; 1998 Dec; 50(4):335-9. PubMed ID: 9830323
    [Abstract] [Full Text] [Related]

  • 8. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.
    Molina JM, Marcelin AG, Pavie J, Heripret L, De Boever CM, Troccaz M, Leleu G, Calvez V, AI454-176 JAGUAR Study Team.
    J Infect Dis; 2005 Mar 15; 191(6):840-7. PubMed ID: 15717257
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA, Akinsete L, Abalaka AD, Keshinro LB, Dutse L, Onyenekwe B, Lhekwaba A, Njoku OS, Kehinde MO, Wambebe CO.
    West Afr J Med; 2002 Mar 15; 21(2):83-6. PubMed ID: 12403023
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.
    Antivir Ther; 2009 Mar 15; 14(3):339-47. PubMed ID: 19474468
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.
    Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, Kagan J.
    Clin Infect Dis; 2005 Mar 15; 40(6):853-8. PubMed ID: 15736019
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.